BioCentury | Mar 15, 2010
Clinical News

NMP22 BladderChek Test: Post-marketing study data

...the cost per tumor detected was $7,692 for cystoscopy alone; $9,557 for cystoscopy with Inverness' NMP22 BladderChek Test...
...Oncology Genitourinary Cancers Symposium in San Francisco. Inverness Medical Innovations Inc. (NYSE:IMA), Waltham, Mass. Product: NMP22 BladderChek Test...
BioCentury | Sep 3, 2007
Company News

Inverness, Matritech deal

...deal was announced. MZT also is eligible for $2 million in revenue milestones. MZT markets NMP22 BladderChek Test...
BioCentury | Jan 23, 2006
Clinical News

NMP22 BladderChek Test diagnostic data

...specificity of NMP22 assay was 49.5% and 87.3%, respectively. Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Test...
BioCentury | Jul 18, 2005
Clinical News

NMP22 BladderChek Test regulatory update

...BladderChek is approved in the U.S., Europe and Canada. Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Test...
BioCentury | Feb 21, 2005
Clinical News

NMP22 BladderChek Test diagnostic data

...In a U.S. study in 1,331 patients at risk for bladder cancer, the NMP22 BladderChek test with cytoscopy...
...89% seen by cytoscopy alone (p=0.26). Of the 79 patients diagnosed with bladder cancer, the NMP22 test...
...patients with 15.8% sensitivity with cytoscopy alone. The cytoscopy alone was significantly more specific vs. NMP22 test...
BioCentury | Sep 27, 2004
Clinical News

NMP22 BladderChek regulatory update

...Matritech Inc. (MZT), Newton, Mass. Product: NMP22 BladderChek Business: Diagnostic Health Canada approved NMP22 BladderChek, an...
...Stellar International Inc. (TSXV:SLX, London, Ontario) has exclusive rights to market the assay in Canada. BladderChek...
BioCentury | Jun 14, 2004
Company News

Matritech, Inverness sales and marketing update

...to hospitals and clinical reference laboratories in the U.S. MZT will continue to sell the NMP22 BladderChek test...
BioCentury | Feb 23, 2004
Clinical News

NMP22 BladderCheck test regulatory update

...MZT received CE Mark approval in the EU for its NMP22 products, including NMP22 BladderChek to...
BioCentury | Jan 12, 2004
Finance

Regressing to normality

...The company markets Quadramet for cancer bone pain, ProstaScint imaging agent for prostate cancer and BladderChek...
BioCentury | Oct 27, 2003
Company News

Matritech, Stellar International Inc. deal

...company SSY received exclusive rights to market NMPS's NMP22 BladderChek test to diagnose and monitor bladder cancer. BladderChek...
Items per page:
1 - 10 of 54